Target influenza with Supemtek▼(Quadrivalent Influenza Vaccine, recombinant prepared in cell culture), the first recombinant influenza vaccine in Europe. Supemtek is manufactured to offer an exact genetic match to the WHO-predicated viral strain haemagglutinin antigen.1,2
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Goggle Play or apple App Store. Adverse events should also be reported to the Sanofi drug safety department on 0800 0902 314. Alternatively send via email to UKemail@example.com
References: 1. Dunkle LM, et al. N Engl J Med. 2017;376:2427–36; 2. Quadrivalent Influenza Vaccine (recombinant, prepared in cell culture) Summary of Product Characteristics. Sanofi Pasteur [November 2020].
MAT-GB-2003360(V1.0) March 2021
Immunisation saves up to 3 million lives every year, it is one of the most cost-effective healthcare investments available.
Sanofi Pasteur supplies healthcare professionals with a range of high quality vaccines and aims to provide the exceptional level of support you would expect from such an experienced vaccine manufacturer.
MAT-GB-2003570(v2.0) | March 2021